BOSTON, March 15, 2016 /PRNewswire/ -- Today, Bayer brings together more than 150 members of the Boston life science community to present its life science innovation and partnership strategy and introduce the newly formed Bayer East Coast Innovation Center. The Center, which will serve as a regional hub to strengthen Bayer's ties to the thriving life science community, expands on the company's existing partnering presence. Today's event is hosted by MassBio, the Massachusetts life science trade association.
"We are excited to engage the broader life science community in Boston and beyond through the Bayer East Coast Innovation Center," said Kemal Malik, member of the Bayer Board of Management responsible for innovation. "By complementing our own capabilities through alliances with excellent partners from industry and academia here in the region, we are well-positioned to translate our combined scientific know-how and research expertise into impactful solutions and medicines for patients."
Bayer's East Coast Innovation Center builds on the company's science and innovation hubs around the world including the U.S. Innovation Center in San Francisco and hubs in Berlin, Beijing, Osaka and Singapore. In both San Francisco and Berlin, Bayer hosts a CoLaborator – a unique incubator space for young life sciences companies with similar therapeutic interests. The new Bayer East Coast Innovation Center will anchor Bayer's presence and enable its teams to deepen relationships and opportunities to influence the discovery and development of new therapeutics.
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Bayer's diverse partnering model has already enabled the company to establish a number of other key relationships across therapeutic areas, including:
American Association for Cancer Research (AACR), with which Bayer has a grants-based partnership seeking novel targets and biomarkers in oncology research.
The Broad Institute of MIT and Harvard, where Bayer teams work closely with Broad researchers in joint projects to discover and develop therapeutic agents that selectively target cancer genome alterations and cardiovascular genomics and use information from cardiovascular genomic studies to identify new therapeutic targets.
CRISPR Therapeutics, with which Bayer announced the creation of a joint venture to discover, develop and commercialize new breakthrough therapies to cure blood disorders, blindness and congenital heart disease.
Dimension Therapeutics, with which Bayer is collaborating to develop gene therapy products for hemophilia A.
